

## Veklury<sup>®</sup> (remdesivir) – Expanded indication

- On January 20, 2022, the FDA approved Gilead's Veklury (remdesivir), for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older and weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, who are not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.
  - Previously, Veklury was approved for the same indication in hospitalized patients only.
- The approval of Veklury for the expanded indication was based on a randomized, double-blind, • placebo-controlled study in 554 adults and 8 pediatric patients who were unvaccinated, nonhospitalized, had mild-to-moderate COVID-19, were symptomatic for COVID-19 for ≤ 7 days, had confirmed SARS-CoV-2 infection, and had at least one risk factor for progression to hospitalization. Patients received 3 days of standard of care + Veklury or placebo. The primary endpoint was the proportion of patients with COVID-19 related hospitalization (defined as at least 24 hours of acute care) or all-cause mortality through day 28.
  - Events occurred in 2 (0.7%) patients treated with Veklury vs. 15 (5.3%) patients with placebo (hazard ratio 0.134, 95% CI: 0.031, 0.586; p = 0.0076). No deaths were observed through day 28.
- The recommended dose of Veklury for the treatment of non-hospitalized adults and pediatric • patients 12 years of age and older and weighing at least 40 kg is a single loading dose of 200 mg on day 1 via intravenous (IV) infusion followed by once-daily maintenance doses of 100 mg from day 2 via IV infusion for a total treatment duration of 3 days.
  - The treatment course of Veklury should be initiated as soon as possible after diagnosis of symptomatic COVID-19 has been made and within 7 days of symptom onset.
  - Refer to the Veklury drug label for dosing recommendations for hospitalized patients.



optumrx.com

OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.